Evaluación del tiempo de protrombina en pacientes tratados con warfarina, atendidos en el Laboratorio Escalabs, setiembre 2016-enero 2017

• Autor: Malca Portales, Karina Lisbeth
• Formato: tesis de grado
• Fecha de Publicación: 2018
• Institución: Universidad Nacional de Trujillo
• Repositorio: UNITRU-Tesis
• Lenguaje: español
• OAI Identifier: oai:dspace.unitru.edu.pe:20.500.14414/10425
• Enlace del recurso: https://hdl.handle.net/20.500.14414/10425
• Nivel de acceso: acceso abierto
• Materia: coeficiente internacional normalizado, warfarina, INR, protrombina

The objective was to evaluate the prothrombin time in patients treated with warfarin, treated in the Escalabs Laboratory in Trujillo, September 2016-January 2017. Method: descriptive and cross-sectional, the sample was 198 patients of both sexes, criteria were considered for the use of information, the prothrombin time was evaluated and standardized using the international normalized coefficient (INR). The results were: 64.14% of the population are women and 35.86% are men. 54.70% of women and 49.30% of men presented optimal values of the INR with a range of 2-3; but 24.79% of women and 19.72% have an INR greater than 3, so it must be monitored to avoid possible bleeding. Warfarin inhibits epoxide reductase and prevents hepatic gammacarboxylation, that is, acts as "antivitamin K" and prevents the formation of blood clots. The prothrombin time test measures the time it takes for a clot to form in a blood sample. The age group was 13.13% males and 19.70% females 55-64 years of age. The 24.75% of the age group of 55-64 years presented optimal values of INR being higher percentage than in other age groups. 50% of all patients presented optimal INR values, with a range of 2-3, however, 28.28% had an INR of 1.50-1.99, so the dose of their medication should be adjusted to avoid future thrombotic events